A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing GW572016 and Letrozole Versus Letrozole in Subjects With Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing GW572016 and Letrozole Versus Letrozole in Subjects With Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2018

At a glance

  • Drugs Lapatinib (Primary) ; Letrozole
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
  • Most Recent Events

    • 18 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 18 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 10 Jan 2018 Planned End Date changed from 1 Dec 2017 to 30 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top